Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Antibiotic for preventing surgical infections proven safe in penicillin-allergic patients

Antibiotic for preventing surgical infections proven safe in penicillin-allergic patients

Stories Aug 20, 2021 4 minutes

Antimicrobial stewardship project highlights need for antibiotic use policies that help suppress drug resistance.

In the 1990s, antimicrobial stewardship programs started appearing at medical institutions around the world to promote the appropriate prescribing of anti-infective medications and address the increasing resistance of viruses, bacteria and fungi to anti-infectives. Vancouver Coastal Health Research Institute scientist, Dr. Tim Lau, explains that concern over antibiotic resistance was growing not only because of unnecessary and excessive use of these specific medications, which fuel bacterial resistance, but also because pharmaceutical companies had all but ceased research and development of new antibiotics.

“New classes of antibiotics are not being developed,” explains Lau, pharmacy lead for ASPIRES (Antimicrobial Stewardship Programme: Innovation, Research, Education, and Safety), the antimicrobial stewardship program for Vancouver Coastal Health (VCH). “The concern is that with increasing bacterial resistance, we will run out of antibiotics to use.”

Dr. Tim Lau is clinical supervisor and clinical pharmacy specialist in infectious diseases and antimicrobial stewardship at VGH, and a clinical professor in the Faculty of Pharmaceutical Sciences and associate member, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine at the University of British Columbia. 

Dr. Jennifer Grant, a medical microbiologist, infectious diseases physician and medical director for ASPIRES, adds that too often, people are prescribed broad-spectrum antibiotics, which are stronger than what they need, and are given them for longer than is required.

“There seems to be a nervousness around prescribing anything less,” she says. 

“Our job is to support health care practitioners in decision-making about prescribing narrow-spectrum antibiotics for a shorter time period because this leads to less resistance while still offering similar health outcomes as broad-spectrum, longer-term antibiotic use.”

One ASPIRES initiative led by Drs. Grant and Lau focused on the antibiotic, cefazolin, and its use pre-operatively for surgery patients at Vancouver General Hospital (VGH). Cefazolin is a standard part of pre-operative care because it is relatively non-toxic, inexpensive, easy to administer and outperforms other antibiotics in preventing surgical site infections. However, the drug is similar to penicillin, which has created hesitancy among surgeons and anesthesiologists around giving it to patients with a reported penicillin allergy. 

Drs. Grant and Lau highlight that although penicillin and cefazolin are similar in chemical structure, there is an evolving understanding based on new research that cefazolin is generally safe for individuals allergic to penicillin. Despite this, alternative antibiotics such as vancomycin and clindamycin are being given, which do not work as well as cefazolin for preventing surgical site infections and tend to be associated with more adverse effects, such as C. difficile infection.

Dr. Jennifer Grant is a medical microbiologist and infectious diseases specialist at VGH, and a clinical associate professor in the Department of Pathology and Laboratory Medicine, and Division of Infectious Diseases, Department of Medicine, Faculty of Medicine at the University of British Columbia.

In February 2018, Grant began approaching anesthesiologists and surgeons at VGH to discuss the safety of cefazolin for patients allergic to penicillin. As a result, some clinicians began using cefazolin for these specific patients and saw positive outcomes. After more discussions with departments throughout VGH, in October 2018, a policy shift was adopted by the hospital and an institution-wide implementation began in which all surgery patients, including those who reported a penicillin allergy, were given cefazolin.

Drs. Grant and Lau studied the effects of the policy shift between 2017 and 2019. Their findings—published in Surgery—showed that of 220 surgery patients with penicillin-anaphylactic histories reviewed prior to the full policy change, no reports of anaphylaxis were documented in any penicillin-allergic patients receiving cefazolin. Furthermore, after the policy was implemented, the researchers found that in 13,919 surgeries, cefazolin usage increased by 18 per cent, while vancomycin and clindamycin decreased by 11 per cent and 62 percent, respectively. 

To accompany the policy shift, ASPIRES also developed and launched an educational campaign about the safety of cefazolin and engaged surgical nurse educators to help educate physicians, nursing and pharmacy staff at VGH. 

“Cefazolin is our number one drug for surgery,” says Grant. “And while the caveat historically was that anyone allergic to penicillin could be allergic to cefazolin, we found that they can actually, safely, take this drug.”

Lau believes that this project was particularly successful because of its multidisciplinary approach.

“We involved anesthesiology, surgery, pharmacy, allergy and immunology, professional practice nursing, VCH’s National Surgical Quality Improvement Program, and of course we had the support of VCH’s Medicine Quality & Safety, and VGH’s Medical Advisory Committee.”
 

Researchers

Tim Lau
Jennifer Grant

Related Articles

Antibiotics taken during labour and delivery not linked to autism

A nano silver bullet for treatment-resistant bacteria

New evidence calls into question vitamin C as a treatment for sepsis

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy